ECSP20052897A - Inhibidores de cd73 - Google Patents

Inhibidores de cd73

Info

Publication number
ECSP20052897A
ECSP20052897A ECSENADI202052897A ECDI202052897A ECSP20052897A EC SP20052897 A ECSP20052897 A EC SP20052897A EC SENADI202052897 A ECSENADI202052897 A EC SENADI202052897A EC DI202052897 A ECDI202052897 A EC DI202052897A EC SP20052897 A ECSP20052897 A EC SP20052897A
Authority
EC
Ecuador
Prior art keywords
inhibitors
pyridazin
dione
pyrimidine
cycloalkyl
Prior art date
Application number
ECSENADI202052897A
Other languages
English (en)
Inventor
Jennifer Marie Howell
Paredes Maria Cristina Garcia
Yan Wang
Robert Dean Dally
Frank George Njoroge
Genshi Zhao
Lawrence Joseph Ii Heinz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP20052897A publication Critical patent/ECSP20052897A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona 5-[5]-[2-cicloalquil]-6-piridazin-3-il]-1H-pirimidin-2,4-diona, o sales aceptables desde el punto de vista farmacéutico de este, que inhiben la actividad de CD73 y son útiles en el tratamiento contra el cáncer.
ECSENADI202052897A 2018-03-01 2020-08-31 Inhibidores de cd73 ECSP20052897A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862636978P 2018-03-01 2018-03-01
US201862775553P 2018-12-05 2018-12-05

Publications (1)

Publication Number Publication Date
ECSP20052897A true ECSP20052897A (es) 2020-09-30

Family

ID=65686120

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202052897A ECSP20052897A (es) 2018-03-01 2020-08-31 Inhibidores de cd73

Country Status (34)

Country Link
US (1) US11028074B2 (es)
EP (1) EP3759096B1 (es)
JP (1) JP6794560B2 (es)
KR (1) KR20200116965A (es)
CN (1) CN111819173B (es)
AU (1) AU2019228473B2 (es)
BR (1) BR112020016066A2 (es)
CA (1) CA3092661C (es)
CL (1) CL2020002158A1 (es)
CO (1) CO2020010191A2 (es)
CR (1) CR20200376A (es)
CY (1) CY1125145T1 (es)
DK (1) DK3759096T3 (es)
DO (1) DOP2020000148A (es)
EC (1) ECSP20052897A (es)
ES (1) ES2909701T3 (es)
HR (1) HRP20220459T1 (es)
IL (1) IL277006B2 (es)
JO (1) JOP20200209A1 (es)
LT (1) LT3759096T (es)
MA (1) MA52413A (es)
MX (1) MX2020009115A (es)
MY (1) MY200200A (es)
PE (1) PE20210177A1 (es)
PH (1) PH12020551464A1 (es)
PL (1) PL3759096T3 (es)
PT (1) PT3759096T (es)
RS (1) RS63073B1 (es)
SG (1) SG11202008366RA (es)
SI (1) SI3759096T1 (es)
TW (1) TWI702954B (es)
UA (1) UA123890C2 (es)
WO (1) WO2019168744A1 (es)
ZA (1) ZA202004805B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3070946T3 (en) 2019-03-12 2026-06-18 Arcus Biosciences Inc Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
EP4021902B1 (en) * 2019-08-29 2024-03-20 Eli Lilly and Company Crystalline forms of a cd73 inhibitor
WO2021113625A1 (en) * 2019-12-06 2021-06-10 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
JP7842698B2 (ja) * 2020-04-23 2026-04-08 オプナ バイオ ソシエテ アノニム Ｃｄ７３調節のための化合物及び方法並びにそれらの表示
JP7564888B2 (ja) 2020-05-01 2024-10-09 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
CN115702150A (zh) * 2020-07-07 2023-02-14 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
CN114057693A (zh) * 2020-08-03 2022-02-18 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
AU2021341258A1 (en) 2020-09-08 2023-04-13 Betta Pharmaceuticals Co., Ltd. CD73 inhibitor and application thereof in medicine
WO2022068929A1 (zh) * 2020-09-30 2022-04-07 武汉人福创新药物研发中心有限公司 嘧啶二酮类化合物及其用途
WO2022090711A1 (en) 2020-10-26 2022-05-05 AdoRx Therapeutics Limited Compounds as cd73 inhibitors
CN114437039A (zh) * 2020-11-05 2022-05-06 武汉人福创新药物研发中心有限公司 Cd73抑制剂及其应用
WO2022095953A1 (zh) * 2020-11-05 2022-05-12 武汉人福创新药物研发中心有限公司 哒嗪炔烃类化合物及其用途
WO2022121914A1 (zh) * 2020-12-10 2022-06-16 上海翰森生物医药科技有限公司 氧代氮环类衍生物调节剂、其制备方法和应用
CN114790197A (zh) * 2021-01-25 2022-07-26 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
WO2022195499A1 (en) * 2021-03-19 2022-09-22 Aurigene Discovery Technologies Limited Substituted pyridazine compounds as cd73 inhibitors
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
CN118829639A (zh) * 2022-03-07 2024-10-22 贝达药业股份有限公司 一种哒嗪类衍生物的晶型、制备方法及其应用
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024006929A1 (en) * 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
JP2025524627A (ja) * 2022-07-14 2025-07-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための複素環化合物
CN117486885B (zh) * 2022-07-26 2026-05-01 中国科学院上海药物研究所 吡唑并嘧啶类化合物的用途
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN118005615A (zh) * 2024-02-07 2024-05-10 中国药科大学 哒嗪类化合物及其制备方法、药物组合物和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200870404A1 (ru) 2006-04-03 2009-04-28 Глэксо Груп Лимитед Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3
EP1860113A1 (en) * 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
LT3399984T (lt) * 2016-01-08 2023-11-10 Arcus Biosciences, Inc. 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives

Also Published As

Publication number Publication date
EP3759096B1 (en) 2022-02-16
TWI702954B (zh) 2020-09-01
CA3092661A1 (en) 2019-09-06
US11028074B2 (en) 2021-06-08
CN111819173B (zh) 2023-06-06
CL2020002158A1 (es) 2020-11-13
KR20200116965A (ko) 2020-10-13
HRP20220459T1 (hr) 2022-05-27
JP2020517655A (ja) 2020-06-18
CR20200376A (es) 2020-10-23
LT3759096T (lt) 2022-04-11
RS63073B1 (sr) 2022-04-29
IL277006B (en) 2022-11-01
BR112020016066A2 (pt) 2020-12-08
TW201945002A (zh) 2019-12-01
SI3759096T1 (sl) 2022-07-29
US20210002257A1 (en) 2021-01-07
SG11202008366RA (en) 2020-09-29
MX2020009115A (es) 2022-11-15
UA123890C2 (uk) 2021-06-16
AU2019228473A1 (en) 2020-08-20
DOP2020000148A (es) 2020-09-15
CA3092661C (en) 2022-07-12
EP3759096A1 (en) 2021-01-06
PH12020551464A1 (en) 2021-09-01
PL3759096T3 (pl) 2022-05-09
MY200200A (en) 2023-12-13
WO2019168744A1 (en) 2019-09-06
CY1125145T1 (el) 2024-02-16
CO2020010191A2 (es) 2020-08-31
PE20210177A1 (es) 2021-01-29
IL277006A (en) 2020-10-29
JP6794560B2 (ja) 2020-12-02
ES2909701T3 (es) 2022-05-10
IL277006B2 (en) 2023-03-01
CN111819173A (zh) 2020-10-23
DK3759096T3 (en) 2022-03-07
PT3759096T (pt) 2022-03-30
AU2019228473B2 (en) 2021-02-25
ZA202004805B (en) 2022-01-26
MA52413A (fr) 2021-01-06
JOP20200209A1 (ar) 2020-08-30

Similar Documents

Publication Publication Date Title
CL2020002158A1 (es) Inhibidores de cd73.
ECSP19033052A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
ECSP19032676A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
MX2018002520A (es) Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo.
CL2019001551A1 (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
UY35834A (es) Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
MX2016011468A (es) Inhibidores de calicreína plasmática humana.
MX2020003868A (es) Compuesto heterociclico como inhibidor de proteina quinasa.
JOP20210050A1 (ar) معدلات تعبير pnpla3
MX386547B (es) Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
JOP20200291A1 (ar) معدلات التعبير عن apol1
MX2019008302A (es) Inhibidores biciclicos de histona desacetilasa.
CO2018006097A2 (es) Pesticidas azoles bicíclicos sustituídos con heterociclo
CL2019002854A1 (es) Compuesto macrocíclico y sus usos.
CO2022000270A2 (es) Inhibidores de enzimas
MX2018003930A (es) Inhibidores de calicreína plasmática humana.
MX2019009354A (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer.
MX2019009266A (es) Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer.
EP3868385C0 (en) GASTRIC CANCER TREATMENT COMPOSITION COMPRISING A SYT11 INHIBITOR AS THE ACTIVE INGREDIENT
MX2019009351A (es) Piridinas sustituidas con heteroarilsulfonilo y su uso en el tratamiento del cancer.
CO2021008535A2 (es) Compuestos de quinolina como inhibidores de quinasas tam y met